Navigating Bispecific Administration: Protocols, Dosage, and Challenges in R/R MM
Amir discusses challenges encountered during the administration process, offering valuable perspectives on the practical considerations and complexities in delivering these innovative therapies.
EP: 1.Case Presentation: Clinical Decision Making in a R/R MM patient
EP: 2.Treatment Options in Late Line Relapsed/Refractory MM Patients
EP: 3.Role of GPRC5D in R/R MM Patients
EP: 4.Case Presentation: Clinical Decision Making in a Patient With R/R MM
Now Viewing
EP: 5.Navigating Bispecific Administration: Protocols, Dosage, and Challenges in R/R MM
EP: 6.Collaborative Care and Access Challenges in Managing R/R MM with GPRC5D Bispecific
EP: 7.Case Presentation: Clinical Decision Making for a Patient With R/R MM
EP: 8.Patient-Centric Care in R/R MM
EP: 9.Guiding Through Challenges: Insights for Caregivers of R/R MM Patients
EP: 10.APPs Focus on Education of Talquetamab Use and Administration in Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
